"Promising Results: Pfizer and BioNTech's Combined COVID-Flu Vaccine Shows Strong Immune Response"

Pfizer and BioNTech have announced that their flu-COVID vaccine has generated a strong immune response against strains of both viruses in an early- to mid-stage trial. The companies plan to proceed with a late-stage trial in the coming months. The vaccine has the potential to simplify immunization practices by addressing two respiratory diseases with a single injection. The trial data showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.